AstraZeneca PLC
AZN
$89.10
$0.490.55%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Net Income | 2.53B | 2.45B | 2.92B | 1.50B | 1.43B |
| Total Depreciation and Amortization | 1.55B | 1.39B | 1.28B | 1.16B | 1.82B |
| Total Amortization of Deferred Charges | -- | -- | -- | 200.00M | -- |
| Total Other Non-Cash Items | 217.00M | -108.00M | -61.00M | 402.00M | 96.00M |
| Change in Net Operating Assets | 835.00M | -345.00M | -426.00M | -350.00M | 41.00M |
| Cash from Operations | 5.13B | 3.39B | 3.71B | 2.91B | 3.38B |
| Capital Expenditure | -686.00M | -659.00M | -429.00M | -708.00M | -417.00M |
| Sale of Property, Plant, and Equipment | 0.00 | 9.00M | 1.00M | 2.00M | 0.00 |
| Cash Acquisitions | -328.00M | -267.00M | -362.00M | -274.00M | -263.00M |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -987.00M | -1.19B | -463.00M | -201.00M | -834.00M |
| Cash from Investing | -2.00B | -2.11B | -1.25B | -1.18B | -1.51B |
| Total Debt Issued | -352.00M | 644.00M | 1.10B | -572.00M | -415.00M |
| Total Debt Repaid | -93.00M | -115.00M | -85.00M | -119.00M | -2.09B |
| Issuance of Common Stock | 5.00M | 4.00M | 8.00M | 23.00M | 4.00M |
| Repurchase of Common Stock | -19.00M | -3.00M | -486.00M | 0.00 | -81.00M |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -1.61B | -10.00M | -3.35B | -3.00M | -1.58B |
| Other Financing Activities | -3.00M | -2.00M | 104.00M | 0.00 | 24.00M |
| Cash from Financing | -2.07B | 518.00M | -2.71B | -671.00M | -4.13B |
| Foreign Exchange rate Adjustments | -12.00M | 29.00M | 25.00M | -61.00M | 20.00M |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 1.05B | 1.83B | -222.00M | 994.00M | -2.24B |